Mycamine
Total Payments
$34,915
Transactions
502
Doctors
348
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $128.55 | 5 | 5 |
| 2017 | $34,787 | 497 | 343 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,421 | 9 | 67.1% |
| Food and Beverage | $8,695 | 489 | 24.9% |
| Space rental or facility fees (teaching hospital only) | $2,800 | 4 | 8.0% |
Payments by Type
Research
$23,421
9 transactions
General
$11,495
493 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| To determine the efficacy and safety of Micafungin versus liposomal amphotericinB (AmBisome) in treating patients with invasive candidiasis or candidaemia | Astellas Pharma Global Development | $16,401 | 4 |
| A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | Astellas Pharma Global Development | $7,020 | 5 |
Top Doctors Receiving Payments for Mycamine — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pediatric Infectious Diseases | Houston, TX | $83.78 | 4 |
| , M.D | Student in an Organized Health Care Education/Training Program | Houston, TX | $76.38 | 4 |
| , M.D | Internal Medicine | Houston, TX | $58.91 | 3 |
| , M.D | Infectious Disease | Houston, TX | $58.24 | 3 |
| , M.D | Pediatric Infectious Diseases | Houston, TX | $58.24 | 3 |
| , M.D | Infectious Disease | Houston, TX | $52.68 | 3 |
| , M.D | Hospitalist | Pueblo, CO | $52.68 | 3 |
| , M.D | Internal Medicine | Houston, TX | $52.68 | 3 |
| , M.D | Internal Medicine | Rochester, MN | $52.68 | 3 |
| , M.D | Internal Medicine | Louisville, KY | $50.78 | 3 |
| , M.D | Internal Medicine | Louisville, KY | $50.78 | 3 |
| , M.D | Specialist | Atlanta, GA | $49.31 | 2 |
| , MD | Hospitalist | Dallas, TX | $49.05 | 3 |
| , MD | Hospitalist | Dallas, TX | $49.05 | 3 |
| , M.D | Student in an Organized Health Care Education/Training Program | Hartford, CT | $43.64 | 2 |
| , MD | Pediatric Infectious Diseases | Houston, TX | $43.22 | 2 |
| , M.D | Infectious Disease | Carmel, IN | $43.07 | 3 |
| , MD | Student in an Organized Health Care Education/Training Program | Houston, TX | $42.72 | 2 |
| , D.O | Internal Medicine | Tulsa, OK | $41.80 | 2 |
| , D.O | Cardiovascular Disease | Tulsa, OK | $41.80 | 2 |
| , D.O | Internal Medicine | Tulsa, OK | $41.80 | 2 |
| , D.O | Internal Medicine | Tulsa, OK | $41.80 | 2 |
| , D.O | Gastroenterology | Tulsa, OK | $41.80 | 2 |
| , D.O | Internal Medicine | Tulsa, OK | $41.80 | 2 |
| John Vann | Cardiovascular Disease | Tulsa, OK | $41.80 | 2 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $23,421
- Astellas Pharma US Inc $11,495
Product Information
- Type Drug
- Total Payments $34,915
- Total Doctors 348
- Transactions 502
About Mycamine
Mycamine is a drug associated with $34,915 in payments to 348 healthcare providers, recorded across 502 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2023. In 2023, $128.55 was paid across 5 transactions to 5 doctors.
The most common payment nature for Mycamine is "Unspecified" ($23,421, 67.1% of total).
Mycamine is associated with 2 research studies, including "To determine the efficacy and safety of Micafungin versus liposomal amphotericinB (AmBisome) in treating patients with invasive candidiasis or candidaemia" ($16,401).